logo-loader
RNS
Diaceutics PLC

Director/PDMR Shareholding

RNS Number : 7937C
Diaceutics PLC
12 November 2026
 

 

Diaceutics PLC

Grant of Share Options/PDMR Shareholdings

New York, Belfast and London, 12 November 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, announces the grant of 976,744 share options over ordinary shares of £0.002 each in the Company (“Share Options”) to certain directors and members of the Company’s senior management team on 23 October 2026, pursuant to the Company’s Employee Share Option Plan (“ESOP”). These awards are made in accordance with the Company’s long term incentive plan as detailed in the Company’s Annual Report.

Share Options were granted as follows:

 

Name

Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Performance Period

Ryan Keeling, CEO

 

301,625

1,640,923

1.92%

3 years from 30 July 2026

Nick Roberts, CFO

195,861

815,196

0.96%

3 years from 30 July 2026

Jordan Clark, CCO

 

 

191,508

521,005

0.61%

3 years from 30 July 2026

Sandra Blake, CMPO and PDMR

93,144

255,730

0.30%

3 years from 30 July 2026

Chris Meenan, CPTO and PDMR

106,668

106,668

0.13%

3 years from 30 July 2026

Susanne Munksted, CPO and PDMR

87,938

412,911

0.48%

3 years from 30 July 2026

 

For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return (“TSR”), the revenue Compound Annual Growth Rate (“CAGR”) and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.

 

The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.

The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.

Following this grant, the total number of share options outstanding in the Company is 7,042,578 representing approximately 8.26% of its current issued share capital of 85,291,958.

 

Enquiries:

 

Diaceutics PLC 

 

Ryan Keeling, Chief Executive Officer

Tel: +44 (0)28 9040 6500 

Nick Roberts, Chief Financial Officer 

investorrelations@diaceutics.com

 

 

Canaccord Genuity Limited (Nomad & Broker)

Tel: +44 (0)20 7253 8000

Simon Bridges, Andrew Potts, Harry Rees

 

 

 

About Diaceutics

At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBBFTMTMBBLF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Holding(s) in Company

3 days, 5 hours ago

Director/PDMR Shareholding

6 days, 1 hour ago

Holding(s) in Company

6 days, 1 hour ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

on 10/12/2026

Holding(s) in Company

on 10/07/2026

3 min read